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Increased activation of the serine-glycine biosyn-
thetic pathway is an integral part of cancer meta-
bolism that drives macromolecule synthesis needed
for cell proliferation. Whether this pathway is under
epigenetic control is unknown. Here we show that
the histone H3 lysine 9 (H3K9) methyltransferase
G9A is required for maintaining the pathway enzyme
genes in an active state marked by H3K9 monome-
thylation and for the transcriptional activation of
this pathway in response to serine deprivation. G9A
inactivation depletes serine and its downstream
metabolites, triggering cell death with autophagy in
cancer cell lines of different tissue origins. Higher
G9A expression, which is observed in various
cancers and is associated with greater mortality in
cancer patients, increases serine production and
enhances the proliferation and tumorigenicity of
cancer cells. These findings identify a G9A-depen-
dent epigenetic program in the control of cancer
metabolism, providing a rationale for G9A inhibition
as a therapeutic strategy for cancer.
INTRODUCTION
Histone lysine methylation has a central role in the control of
gene transcription. The histone lysine methylation state is
controlled by histone lysine methyltransferases (KMTs) and
demethylases (KDMs). The enzymatic reactions catalyzed by
KMTs and KDMs depend on metabolic coenzymes including
S-adenosylmethionine (SAM), flavin adenine dinucleotide896 Cell Metabolism 18, 896–907, December 3, 2013 ª2013 Elsevier(FAD), and a-ketoglutarate (a-KG). KMTs catalyze lysine methyl-
ation using SAM as the methyl group donor, whereas LSD
(KDM1A and KDM1B) and JmjC domain-containing KDMs
(KDM2-KDM8) require FAD and a-KG for demethylation, respec-
tively (Black et al., 2012; Mosammaparast and Shi, 2010). Their
dependence on metabolic coenzymes suggests that KMTs and
KDMs could reprogram gene expression in response to changes
in cellular metabolism. This notion has also led to the provocative
hypothesis that KMTs and KDMs may contribute to metabolic
control through transcriptional regulation (Teperino et al., 2010).
G9A, also known as EHMT2, is a H3K9 methyltransferase
that has a primary role in catalyzing monomethylation and dime-
thylation of H3K9 (H3K9me1 and H3K9me2) in euchromatin
(Peters et al., 2003; Rice et al., 2003; Shinkai and Tachibana,
2011; Tachibana et al., 2002), with H3K9me1 being associated
with transcriptional activation and H3K9me2 with transcriptional
repression (Black et al., 2012; Mosammaparast and Shi, 2010).
Elevated levels of G9A expression have been observed in
many types of human cancers, and G9A knockdown has been
shown to inhibit the proliferation of cancer cell lines (Chen
et al., 2010; Cho et al., 2011; Huang et al., 2010; Kondo et al.,
2008). The molecular basis of G9A action in the control of cancer
cell proliferation is not well understood. In this study, we identify
an essential role of G9A in sustaining cancer cell survival and
proliferation by transcriptional activation of the serine-glycine
biosynthetic pathway. Our findings provide direct evidence for
a G9A-dependent epigenetic program in the control of amino
acid production and cancer metabolism.
RESULTS
G9A Is Essential for Sustaining Cancer Cell Proliferation
and Survival
We examined the role of G9A in cell survival and proliferation in
human cancer cell lines of different tissue origins, including theInc.
Figure 1. G9A Inhibition or Silencing
Induces Autophagy
(A) Electron micrographs of U2OS cells with or
without 5 mM BIX for 24 hr.
(B) Immunofluorescence of LC3B-positive auto-
phagosomes in U2OS cells with or without 5 mM
BIX for 24 hr.
(C) Immunoblotting of LC3B in U2OS cells with or
without 5 mM BIX or 10 mM chloroquine (CQ) for
24 hr. LC3B-II levels were quantified against
a-tubulin.
(D) Immunoblotting of G9A and LC3B in U2OS and
SHEP1 cells expressing GFP shRNA (GFP-sh) or
individual G9A-sh sequences. G9A and LC3B-II
levels were quantified against b-actin.
(E) Fluorescence and quantification of LC3B-
positive autophagosomes in U2OS/mCherry-
EGFP-LC3B cells with or without G9A knockdown.
Error bars represent SD (n = 100 cells). **p < 0.001.
See also Figures S1 and S2.
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G9A Control of Serine Metabolismbladder (J82), bone (U2OS), brain (U251), breast (MCF10A and
MCF7), cervix (HeLa), colon (HCT116 and RKO), liver (Hep2G),
lung (H1299), and sympathetic nervous system (BE(2)-C, SMS-
KCNR, and SHEP1). We treated these cell lines with BIX01294
(BIX), a small molecule inhibitor of G9A (IC50 = 1.7 mM) (Kubicek
et al., 2007). BIX at 2–5 mM significantly reduced the global
levels of H3K9me1 and H3K9me2 (Figure S1A available online)
and completely inhibited the proliferation of all the cancer
cell lines examined (Figure S1B for representative cell lines).
In addition, we observed a significant decrease in cell survival
following BIX treatment (Figure S1C, BIX-5 mM_5d). To confirm
that BIX targets G9A to inhibit cell proliferation and survival, we
examined the effect of G9A silencing by small hairpin RNA
(shRNA). G9A knockdown exerted a pronounced inhibitory
effect on cell proliferation and survival (Figures S1D–S1G).
Together, these findings indicate an essential role of G9A in
sustaining cell proliferation and survival in a wide range of cancer
cell lines.
G9A Inhibition or Silencing Induces Autophagy
An early and prominent morphological feature of the cells with
G9A inhibition or silencing was the appearance of numerous
cytoplasmic vesicles and vacuoles (Figures S1C and S1G)
that morphologically resemble autophagosomes, a double-
membraned structure that sequesters cellular organelles,
proteins, and/or lipids during autophagy. Thus, we examined
the possibility that G9A inhibition or silencing might induceCell Metabolism 18, 896–907,autophagy by electron microscopy for
ultrastructural morphology, by immuno-
blotting for detecting the lipidation of
LC3 (microtubule-associated protein light
chain 3), and by immunofluorescence for
monitoring the formation of LC3-positive
puncta. LC3 is the mammalian homolog
of the yeast autophagy-related protein
Atg8 and is proteolytically processed to
LC3-I by the Atg4 protease following
translation. Upon autophagy induction,LC3-I is converted to the lipidated LC3-II form, which is then
incorporated into the autophagosomal membrane, resulting in
the redistribution of LC3 from a diffuse pattern to a punctate
pattern. Mammalian cells express three LC3 isoforms (LC3A,
LC3B, and LC3C), with LC3B-II levels correlating with the
steady-state levels of autophagosomes (Klionsky et al., 2008;
Mizushima et al., 2010).
Electron microscopy revealed numerous double-membraned
vacuoles in BIX-treated cells that contained fragments of
the endoplasmic reticulum and other cytoplasmic components
(Figure 1A). Immunofluorescence confirmed that these vesicles
and vacuoles were LC3B positive (Figure 1B). To determine
whether the accumulation of autophagosomes resulted from
an increase in autophagosome formation or from a block in
autophagosome turnover, we examined BIX-induced LC3B-II
production in the presence or absence of chloroquine (CQ),
which blocks lysosomal acidification and thus degradation
of autophagosomal components. The presence of CQ further
increased LC3B-II levels in BIX-treated cells (Figure 1C),
indicating that BIX increased LC3B-II production rather than
blocking its degradation.
Dose-titration and time course studies revealed that different
tumor cell lines varied in their sensitivity to BIX. For the most
sensitive SHEP1 and U2OS cells, BIX as low as 1 mM triggered
significant levels of autophagy, as determined by LC3B-II pro-
duction (Figure S2A). The maximal level of autophagy occurred
at 6 hr (SHEP1 and U2OS) or 24 hr (HeLa) following 5 mM BIXDecember 3, 2013 ª2013 Elsevier Inc. 897
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G9A Control of Serine Metabolismtreatment (Figure S2B). We further confirmed the ability of BIX to
induce autophagy with immortalized Atg5+/+ and Atg5/mouse
embryonic fibroblasts (MEFs). Atg5 is required for autophago-
some formation (Kuma et al., 2004; Mizushima et al., 2001).
BIX at the concentrations of 2–5 mM was able to induce LC3B-
positive puncta inAtg5+/+, but not inAtg5/, MEFs (Figure S2C).
To verify that BIX targets G9A to induce autophagy, we exam-
ined the effect of BIX on cells with G9A overexpression. Both
SHEP1 and U2OS cells overexpressing G9A were highly resis-
tant to BIX-induced autophagy, as evidenced by a significant
reduction in LC3B-II levels following BIX treatment compared
to control cells (Figure S2D). Additionally, cells with G9A
silencing fully recapitulated the autophagy phenotype induced
by BIX, showing a significant increase in the production of
LC3B-II (Figure 1D) and LC3B-positive puncta (Figure 1E).
Collectively, these results demonstrate that G9A inhibition or
silencing induces cell death with autophagy.
G9A Inhibition or Silencing Transcriptionally Represses
Serine-Glycine Biosynthesis
To investigate the molecular basis of autophagy induction by
G9A inhibition, we examined the kinase activity of the mamma-
lian target of rapamycin complex 1 (mTORC1), which has amajor
role in the control of autophagy by integrating a wide range of
signals including concentrations of nutrients and growth factors
(He and Klionsky, 2009; Kim and Guan, 2011; Rabinowitz and
White, 2010). mTORC1 inhibits autophagy by suppressing the
autophagy-activating kinase ULK1. Nutrient or growth factor
deprivation inhibits mTORC1 activity, thereby activating ULK1
and inducing autophagy. Immunoblotting revealed that BIX
significantly inhibited mTORC1 kinase activity as demonstrated
by a marked decrease in the phosphorylation of the ribosome
protein S6 kinase (S6K) (Figure S3A), a key mTORC1 substrate.
This finding suggests that G9A inhibition triggers autophagy
by interfering with cell growth or survival signals upstream of
mTORC1.
Given the role of G9A in epigenetic control of transcription, we
performed microarray profiling to identify potential G9A targets
involved in autophagy induction. A total of 615 BIX-responsive
genes (R±1.50-fold, p < 0.01) were identified, with 302 genes
being upregulated and 313 downregulated (Table S1). Gene
Ontology (GO) analysis revealed that among the genes down-
regulated by BIX, those within the serine-glycine biosynthetic
pathway were significantly enriched (Figure 2A), including phos-
phoglycerate dehydrogenase (PHGDH), phosphoserine amino-
transferase 1 (PSAT1), phosphoserine phosphatase (PSPH),
and serine hydroxymethyltransferase 2 (SHMT2) (Figure 2B).
We confirmed the ability of BIX to downregulate mRNA expres-
sion of these genes by quantitative reverse-transcription PCR
(qRT-PCR) in four different cancer cell lines (Figures 2C and
S3B). Time course studies revealed significant downregulation
of these genes within 2 and 6 hr of BIX treatment in U2OS and
HeLa cells, respectively (Figure 2C), which occurred at least
several hours before most of the cells underwent autophagy
(Figure S2B). We noticed that SHMT1, though downregulated
in HeLa, SHEP1, and U2OS cells, was activated in BE(2)-C cells
following BIX treatment (Figure S3B). The significance of this
apparently cell-type-dependent regulation of SHMT1 expression
is currently under investigation. In agreement with themicroarray898 Cell Metabolism 18, 896–907, December 3, 2013 ª2013 Elsevierand qRT-PCR data, we observed a significant decrease in
PHGDH protein levels in BIX-treated cells (Figure S3C). Similarly,
G9A silencing resulted in marked downregulation of the same
group of genes at both mRNA and protein levels (Figures 2D,
S3D, and S3E).
Chromatin immunoprecipitation and quantitative PCR (ChIP-
qPCR) assay revealed that BIX treatment significantly reduced
the H3K9me1 levels around the transcriptional start sites
(TSSs) of PHGDH and PSAT1 (Figure 2E, H3K9me1). By
contrast, H3K9me2 levels in the same regions were either
unchanged or significantly increased following BIX treatment
(Figure 2E, H3K9me2). Together, these results indicate that the
serine-glycine biosynthetic pathway is under the direct tran-
scriptional control of G9A, primarily through the regulation of
H3K9me1 levels associated with the pathway enzyme genes.
Supplemental Serine Rescues the Cell Death Phenotype
of G9A Inhibition
The serine-glycine biosynthetic pathway is an important source
of precursors and coenzymes for the biosynthesis of amino
acids, nucleotides, and lipids (de Koning et al., 2003; Kalhan
and Hanson, 2012) and is crucial for cancer cell survival and pro-
liferation (Locasale, 2013; Locasale et al., 2011; Pollari et al.,
2011; Possemato et al., 2011). In addition, amino acid depriva-
tion is a major trigger of autophagy (Kim and Guan, 2011).
Thus, we investigated the possibility that suppression of this
biosynthetic pathway might be a cause of the cell death pheno-
type induced by G9A inhibition or silencing. Gas chromatog-
raphy-mass spectrometry (GC-MS) analysis revealed that only
serine and glycine levels were significantly reduced in U2OS
cells within 4 hr of BIX treatment (Figure 3A), demonstrating
that G9A activity is essential for maintaining the intracellular
steady-state levels of serine and glycine. We further assessed
the activity of this biosynthetic pathway by [U-13C] glucose flux
analysis using liquid chromatography-tandem mass spectrom-
etry (LC-MS/MS). BIX treatment significantly decreased the
incorporation of [U-13C] glucose into 3-phosphoserine and
serine (Figure 3B). Importantly, addition of serine to the culture
medium significantly diminished the effect of BIX (Figures 3C
and 3D) or G9A silencing (Figure 3E) on cell proliferation and
autophagy in all the cancer cell lines examined. By contrast,
supplemental glycine had only a small protective effect on
BIX-treated cells, and addition of both serine and glycine was
no more effective than adding serine alone (Figures 3F, S4A,
and S4B). We confirmed these findings with cell-permeable
methyl-serine-ester and methyl-glycine-ester (Figure 3G). Other
individual amino acid supplements all failed to prevent cell death
with autophagy induced by BIX (Figures 3F, S4A, and S4C),
providing further evidence for the specificity of serine action.
The observation that serine, but not glycine, was able to
rescue the cell death phenotype suggests that the production
of 5,10-methylenetetrahydrofolate (5,10-MTHF) might be crucial
for cell survival and proliferation. The interconversion between
serine and glycine is catalyzed by SHMT: serine conversion to
glycine generates 5,10-MTHF, whereas glycine conversion to
serine consumes 5,10-MTHF (Figure 3H). To test this idea, we
generated SHEP1 cells overexpressing SHMT1, a cytoplasmic
enzyme, or SHMT2, a predominantly mitochondrial enzyme
(Figure 3I). Their overexpression alone had no significant effectInc.
Figure 2. G9A Inhibition or Silencing Represses Serine-Glycine Biosynthesis
(A) GO analysis of downregulated BIX-responsive genes (enrichment fold >2.0, p < 0.01).
(B) Serine-glycine biosynthetic pathway with the indicated fold changes in mRNA expression determined by microarray.
(C and D) qRT-PCR analysis of mRNA expression of the pathway enzyme genes in U2OS and HeLa cells with or without 5 mM BIX (C) or G9A silencing (D).
Error bars represent SD (n = 3).
(E) ChIP-qPCR analysis of H3K9me1 and H3K9me2 levels at the promoters of PHGDH and PSAT1 in U2OS cells with or without 5 mM BIX for 4 hr. Data on the
GAPDH coding region are shown as positive control. Dashed line indicates IgG control. Error bars represent SD of triplicate and are representatives of two
independent experiments.
*p < 0.01, **p < 0.001. See also Figure S3, Table S1, and Table S3.
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G9A Control of Serine Metabolismon BIX-induced cell death (Figure 3J). However, overexpression
of SHMT2, but not SHMT1, synergized with supplemental serine
to enhance cell survival and proliferation in the presence of BIX
(Figure 3J). This observation is consistent with our model, since
previous studies have suggested that SHMT2 has a major role inCell Mthe conversion of serine to glycine and 5,10-MTHF, whereas
SHMT1 primarily catalyzes the conversion of glycine to serine
(Herbig et al., 2002; Narkewicz et al., 1996; Pfendner and Pizer,
1980; Stover et al., 1997; Tibbetts and Appling, 2010; Yoshida
and Kikuchi, 1970). Collectively, these results indicate thatetabolism 18, 896–907, December 3, 2013 ª2013 Elsevier Inc. 899
Figure 3. Supplemental Serine Rescues the
Phenotype of G9A Inhibition or Silencing
(A) GC-MS analysis of amino acid levels in U2OS
cells with or without 5 mM BIX for 4 hr. Error bars
represent SD (n = 6).
(B) LC-MS/MS analysis of [U-13C] glucose flux into
3-phosphoserine (pSer) and serine (Ser) biosyn-
thesis in U2OS cells with or without 5 mM BIX for
16 hr. The fraction of labeled to total pSer and Ser,
13C/(13C + 12C), was calculated and normalized to
control. Error bars represent SD (n = 3).
(C) Growth assay of SHEP1 and U2OS cells with or
without 5 mM BIX or supplemental serine (Ser).
Error bars represent SD (n = 4).
(D) Immunoblotting of LC3B in the cell samples
from (C). LC3B-II levels were quantified against
a-tubulin.
(E) Growth assay of the indicated cell lines with
G9A silencing in the presence or absence of sup-
plemental serine for 4 days. Dashed line indicates
the number of cells plated at time zero. Error bars
represent SD (n = 4).
(F and G) Growth assay of U2OS cells in the
presence of 5 mM BIX with or without the indi-
cated supplemental amino acids for 2 days. Gly,
glycine; Gly-ester, methyl-glycine-ester; Ser,
serine; Ser-ester, methyl-serine-ester. Dashed line
(F) indicates the number of cells plated at time
zero. Error bars represent SD (n = 4).
(H) Schematic of the interconversion between
serine and glycine. THF, tetrahydrofolate; 5,10-
MTHF, 5,10-methylenetetrahydrofolate.
(I) qRT-PCR analysis of SHMTmRNA expression in
SHEP1 cells overexpressing SHMT1 or SHMT2.
Error bars represent SD (n = 3).
(J) Growth assay of SHEP1 cells expressing GFP,
SHMT1, or SHMT2 in the presence of 5 mM BIX
with or without supplemental Gly-ester or Ser-
ester. Dashed line indicates the number of cells
plated at time zero. Error bars represent SD (n = 3).
*p < 0.01, **p < 0.001. See also Figure S4.
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G9A Control of Serine Metabolismmaintaining the production of serine and its downstream metab-
olites, including 5,10-MTHF, is a major mechanism by which
G9A sustains cancer cell survival and proliferation.
G9A Is a Key Component of the Serine Deprivation
Response, Linking Serine Production, Ribosome
Biogenesis, and Cell-Cycle Progression
It has been shown recently that serine deprivation leads to tran-
scriptional activation of the serine biosynthetic pathway (Ye
et al., 2012; Figure 4A). In light of our findings above, we asked
whether G9A has a role in activation of this pathway in response
to serine deprivation. Addition of BIX completely abrogated the
induction of PHGDH and PSAT1 by serine deprivation (Figures
4B and 4C), supporting a physiological function of G9A in medi-
ating the serine deprivation response.
Amino acid availability controls the rates of protein synthesis
and cell growth (Kilberg et al., 2005), and it has been reported900 Cell Metabolism 18, 896–907, December 3, 2013 ª2013 Elsevier Inc.recently that G9A is required for activation
of rRNA transcription (Yuan et al., 2007), a
rate-limiting step in ribosome biogenesis.We therefore asked whether G9A has a role in linking serine
metabolism to ribosome biogenesis and cell growth. To test
this idea, we performed temporal transcriptome profiling of
BIX-responsive genes by RNA sequencing (RNA-seq), which
revealed distinctive patterns of gene expression in cells that
were treated with BIX for 6 or 24 hr (Figure 4D). In agreement
with the microarray data shown above (Figure 2A; Table S1),
GO analysis of the genes downregulated by BIX at 6 hr revealed
significant enrichment of genes within the serine biosynthetic
pathway (Figure 4E; Table S2). However, cells treated with BIX
for 24 hr displayed a gene expression pattern characterized by
significant downregulation of genes that control cell-cycle pro-
gression (Figure 4F), including cyclins A2 and B2, and CDC25C
(Table S2). We confirmed the RNA-seq result by qRT-PCR,
which showed sequential downregulation of serine synthesis
and cell-cycle genes following BIX treatment (Figure 4G). We
also confirmed the time-dependent downregulation of cyclins
Figure 4. G9A Links Serine Production,
Ribosome Biogenesis, and Cell Proliferation
(A) qRT-PCRanalysis of PHGDH andPSAT1mRNA
levels in SHEP1 cells cultured in serine-deficient
(Ser) medium for 0, 2, 6, and 24 hr. Error bars
represent SD (n = 3).
(B) qRT-PCR analysis of PHGDH mRNA levels in
SHEP1 cells cultured in Ser medium with or
without 5 mMBIX or supplemental serine for 0, 2, 6,
and 24 hr. Error bars represent SD (n = 3).
(C) Immunoblotting of PHGDH and PSAT1 in
SHEP1 cells cultured in control (with serine)
or Ser medium with or without 5 mM BIX or sup-
plemental serine for 24 hr. PHGDH and PSAT1
levels were quantified against a-tubulin.
(D) Heatmap showing differential gene expression
in U2OS cells without (control) or with 5 mM BIX
for 6 (BIX6h) or 24 hr (BIX24h).
(E and F) GO analysis of downregulated BIX-
responsive genes at the 6 hr (E) or 24 hr (F) time
point. Shown are top ten GO biological process
terms.
(G and H) qRT-PCR (G) and immunoblot (H)
analyses of cell-cycle genes in SHEP1 cells with or
without 5 mM BIX for the indicated time. Error bars
in (G) represent SD (n = 3).
(I) GO analysis of the genes downregulated by
BIX at 24 hr versus 6 hr. Shown are top ten GO
biological process terms.
See also Table S2 and Table S3.
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G9A Control of Serine MetabolismA2 and B1 by immunoblotting (Figure 4H). Importantly, we found
marked downregulation of genes involved in ribosome biogen-
esis in cells treated with BIX for 24 hr compared to those treated
for 6 hr (Figure 4I; Table S2), a finding consistent with the
reported role of G9A in activation of rRNA transcription (Yuan
et al., 2007). Collectively, these results suggest a key role of
G9A in coupling serine sensing to the transcription of genes
that control protein synthesis and cell proliferation.
G9A Promotes Cell Proliferation and Tumorigenicity
G9A is overexpressed in various human cancers (Chen et al.,
2010; Cho et al., 2011; Huang et al., 2010; Kondo et al., 2008),Cell Metabolism 18, 896–907,and it has been reported recently that
elevated levels of G9A expression posi-
tively correlate with disease progression
and poor prognosis in lung cancer (Chen
et al., 2010). In line with these reports,
we found that higher G9A expression
was significantly associated with reduced
overall survival in neuroblastoma patients
(Figure 5A). These observations prompted
us to investigate the functional conse-
quence of high G9A expression. Ectopic
expression of G9A in SHEP1 and U2OS
cells significantly increased cell prolifera-
tion (Figure 5B) and the expression of
genes that promote cell-cycle progres-
sion (Figure 5C), indicating that high G9A
expression alone is sufficient to confer
a growth advantage to cancer cells. More-over, G9A overexpression markedly enhanced the anchorage-
independent growth (Figure 5D) and tumorigenicity (Figures 5E
and 5F) of SHEP1 and U2OS cells, demonstrating that G9A
has transforming potential. Together, our results from both
human primary tumors and cell lines suggest an oncogenic
function of G9A in cancer development.
Activation of the Serine-Glycine Biosynthetic Pathway
Is Essential for the Oncogenic Activity of G9A
Given the critical role of the serine-glycine biosynthetic pathway
in sustaining cancer cell survival and proliferation (Locasale
et al., 2011; Pollari et al., 2011; Possemato et al., 2011), we askedDecember 3, 2013 ª2013 Elsevier Inc. 901
Figure 5. G9A Promotes Cell Proliferation
and Tumorigenicity
(A) Kaplan-Meier overall survival for G9A/EHMT2
expression in primary neuroblastoma tumors
(Versteeg NB88 data set).
(B) Growth assay of SHEP1 and U2OS cells with or
without G9A overexpression. Error bars represent
SD (n = 4).
(C) qRT-PCR analysis of cyclin A2 and B1 mRNA
levels in SHEP1 cells with or without G9A over-
expression. Error bars represent SD (n = 3). **p <
0.001.
(D) Soft agar assay of SHEP1 and U2OS cells with
or without G9A overexpression. Shown are rep-
resentatives of three independent experiments.
(E and F) Xenograft assay of SHEP1 and U2OS
cells with or without G9A overexpression. Images
(E) were taken on day 42 after inoculation. Tumor
weight (F) was analyzed by scatterplot with hori-
zontal lines indicating the mean.
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G9A Control of Serine Metabolismwhether elevated levels of G9A lead to increased activation of
this pathway and whether this is a major mechanism for the
oncogenic activity of G9A. Ectopic expression of G9A in
SHEP1 and U2OS cells markedly increased the mRNA (Fig-
ure 6A) and protein (Figure 6B) levels of the pathway enzyme
genes. Moreover, ChIP in combination with DNA sequencing
(ChIP-seq) revealed a significant increase in H3K9me1 levels
at these gene loci (Figure 6C for PHGDH and SHMT2). We
observed no significant change in H3K9me2 levels in the same
regions (Figure 6C). These results suggest that G9A activates
the expression of the pathway enzyme genes by increasing the
H3K9me1 levels associated with their loci. As expected, G9A
overexpression significantly increased the intracellular levels of
serine and glycine (Figure 6D), and the flux of glucose into the
serine biosynthetic pathway (Figure 6E).
To determine whether the oncogenic function of G9A depends
on its ability to activate the serine-glycine pathway, we silenced
the expression of PHGDH or PSAT1 in G9A-overexpressing
U2OS cells by shRNA (Figures 7A and 7B). Knockdown of either
PHGDH or PSAT1 abolished the ability of G9A to promote cell
proliferation in a manner dependent on levels of PHGDH or
PSAT1 downregulation (Figures 7C and 7D). In fact, G9A-over-
expressing cells with more than 90% of PHGDH or PSAT1
knockdown failed to proliferate in the absence of supplemental
serine (Figures 7C and 7D). We obtained essentially the same
results with G9A-overexpressing SHEP1 (Figures S5A–S5D).
Collectively, these data demonstrate that G9A promotes cell
proliferation by transcriptionally activating the serine-glycine
biosynthetic pathway.
The serine biosynthetic genes are direct transcriptional targets
of activating transcription factor 4 (ATF4) (Adams, 2007; Seo
et al., 2009; Ye et al., 2012), which is activated in response to
amino acid deprivation (Kilberg et al., 2009). It has been shown
that ATF4 knockdown or deficiency led to lower expression of
serine biosynthetic enzymes (Ye et al., 2012), suggesting an
essential role of ATF4 in maintaining transcriptional activation
of this pathway. To examine the role of ATF4 in G9A action, we902 Cell Metabolism 18, 896–907, December 3, 2013 ª2013 Elseviersilenced ATF4 expression in G9A-overexpressing U2OS (Fig-
ure 7E) or SHEP1 cells (Figures S5E), which resulted in marked
downregulation of PHGDH and PSAT1 at both mRNA and pro-
tein levels (Figures 7E and 7F and S5E and S5F). ATF4 silencing
also significantly reduced the proliferation of G9A-overexpress-
ing U2OS (Figure 7G) or SHEP1 cells (Figure S5G). Together,
these results indicate that ATF4 is required for G9A to transcrip-
tionally activate serine biosynthesis and to stimulate cell
proliferation.
DISCUSSION
In this study, we show that the histone H3K9 methyltransferase
G9A is essential for transcriptional activation of the serine-
glycine biosynthetic pathway by specifically marking the
pathway enzyme genes with H3K9me1, an epigenetic marker
associated with active chromatin (Black et al., 2012; Mosamma-
parast and Shi, 2010). We further present evidence that G9A is a
component of the molecular pathway that couples serine
sensing to the transcriptional control of serine production, ribo-
some biogenesis, and cell proliferation. Finally, we provide
evidence that G9A has an oncogenic function in cancer develop-
ment by conferring survival and growth advantages to tumors
through increasing the production of serine and its downstream
metabolites. Our study uncovers an epigenetic mechanism for
the control of amino acid metabolism and provides a molecular
explanation for the functional significance of G9A overexpres-
sion observed in various human cancers (Chen et al., 2010;
Cho et al., 2011; Huang et al., 2010; Kondo et al., 2008).
Cell growth and proliferation depend on protein synthesis,
which must in turn match the cellular nutritional status including
amino acid availability (Grummt and Ladurner, 2008; Kilberg
et al., 2005). The mechanistic connection between these cellular
processes remains to be clarified. Our study suggests an epige-
netic mechanism for the control of ribosome biogenesis and cell
proliferation in response to serine abundance. We show that
G9A is essential for the serine deprivation response that leadsInc.
Figure 6. G9A Transcriptionally Activates
Serine-Glycine Biosynthesis
(A) qRT-PCR analysis of mRNA levels of serine-
glycine biosynthetic enzyme genes in SHEP1 and
U2OS cells with or without G9A overexpression.
Error bars represent SD (n = 3).
(B) Immunoblotting of PHGDH and PSAT1 in
SHEP1 and U2OS cells with or without G9A
overexpression. PHGDH and PSAT1 levels were
quantified against a-tubulin.
(C) ChIP-seq tag profiles for H3K9me1 and
H3K9me2 levels in the PHGDH and SHMT2 loci in
U2OS cells with or without G9A overexpression.
Horizontal bars represent chromatin regions in
which H3K9 methylation levels are significantly
changed (G9A/GFP), and the numbers indicate
fold enrichment.
(D) GC-MS analysis of serine and glycine levels in
U2OS cells with or without G9A overexpression.
Error bars represent SD (n = 6).
(E) LC-MS/MS analysis of [U-13C] glucose flux
into 3-phosphoserine (pSer) and serine (Ser)
biosynthesis in U2OS cells with or without G9A
overexpression. The fraction of labeled to total
pSer and Ser, 13C/(13C + 12C), was calculated
and then normalized to GFP control. Error bars
represent SD (n = 3).
*p < 0.05, **p < 0.001. See also Table S3.
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G9A Control of Serine Metabolismto transcriptional activation of genes for serine biosynthesis.
Moreover, we show that G9A activity or expression levels affect
serine production and cell proliferation. Specifically, G9A inhibi-
tion initiated a transcriptional program that results in sequential
repression of genes required for serine production, ribosome
biogenesis, and cell-cycle progression, leading to lower levels
of serine biosynthesis and cell growth arrest. Conversely, G9A
overexpression activated genes for serine biosynthesis and
cell-cycle progression, leading to higher levels of serine produc-
tion and cell proliferation. These results are of particular interest
in the context of recent work showing that G9A is required for
activation of rRNA transcription (Yuan et al., 2007). Thus, we
suggest that G9A-mediated H3K9 methylation serves as a key
link between amino acid sensing and transcriptional control of
ribosome biogenesis and cell proliferation.
Also importantly, we show that G9A requires ATF4 for tran-
scriptional activation of the serine biosynthetic pathway and for
stimulation of cell proliferation. ATF4 has a key role in the cellular
response to amino acid limitation, which leads to increased
ATF4 expression primarily at the translational level. ATF4 in
turn transcriptionally activates a large number of genes includingCell Metabolism 18, 896–907,those for amino acid synthesis and trans-
port (Harding et al., 2003; Kilberg et al.,
2009; Ye et al., 2012). Although themech-
anistic detail remains to be defined, the
observed functional connection between
G9A and ATF4 provides further evidence
for G9A as a component of the signaling
pathway that responds to amino acid
abundance.
It is well documented that cancer cells
alter cellular metabolism to meet thebiosynthetic challenge of growth and proliferation (DeBerardinis
et al., 2008). Cancer metabolism is characterized by aerobic
glycolysis with a high rate of glucose consumption and lactate
production (Warburg, 1956). It is now increasingly recognized
that a major function of aerobic glycolysis is to divert glycolic
intermediates for the biosynthesis of macromolecules needed
for cell growth and proliferation (Cairns et al., 2011; Vander
Heiden et al., 2009). Accumulated evidence suggests that
increased activation of the serine-glycine biosynthetic pathway
is an important part of cancer metabolism (Kalhan and Hanson,
2012; Locasale, 2013). In addition to generating serine and
glycine for the biosynthesis of proteins, purines (via one-carbon
units), and lipids (via phosphatidylserine), this pathway pro-
duces equimolar amounts of reduced nicotinamide adenine
dinucleotide (NADH), a-KG, and 5,10-MTHF (Figure 7H). These
metabolites have critical roles in the control of cellular meta-
bolism for cell proliferation and survival: NADH participates in
ATP production and redox regulation (Corkey and Shirihai,
2012); a-KG supplies carbon to the tricarboxylic acid (TCA) cycle
for the generation of many essential biosynthetic precursors
(DeBerardinis et al., 2008); and 5,10-MTHF is a coenzyme forDecember 3, 2013 ª2013 Elsevier Inc. 903
Figure 7. Activation of Serine-Glycine Biosynthesis Is Required for G9A to Promote Cell Proliferation
(A and B) Immunoblotting of PHGDH and PSAT1 in G9A-overexpressing U2OS cells with PHGDH (A) or PSAT1 (B) knockdown. PHGDH and PSAT1 levels
were quantified against a-tubulin.
(C and D) Growth assay of G9A-overexpressing U2OS cells with PHGDH (C) or PSAT1 (D) knockdown. Error bars represent SD (n = 3).
(E and F) Immunoblot (E) and qRT-PCR (F) analysis of the expression of serine-glycine biosynthetic enzyme genes in G9A-overexpressing U2OS cells with
ATF4 knockdown. **p < 0.001.
(G) Growth assay of G9A-overexpressing U2OS cells with ATF4 knockdown. Error bars represent SD (n = 3).
(H) Model for G9A regulation of serine metabolism. 3-PG, 3-phosphoglycerate; 3-PHP, 3-phosphohydroxypyruvate; 3-PSer, 3-phosphoserine; OAA,
oxaloacetate; Ptd-Ser, phosphatidylserine.
See also Figure S5 and Table S3.
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G9A Control of Serine Metabolismthe only cellular pathway of de novo thymidylate biosynthesis
catalyzed by thymidylate synthase and a major source of one-
carbon units for purine synthesis and methyl group biogenesis,
such as the generation of SAM, a coenzyme for histone and
DNA methyltransferases (Kalhan and Hanson, 2012; Teperino
et al., 2010; Tibbetts and Appling, 2010; Touroutoglou and
Pazdur, 1996).904 Cell Metabolism 18, 896–907, December 3, 2013 ª2013 ElsevierImportantly, we present evidence suggesting that the genera-
tion of 5,10-MTHF is crucial for the function of the serine-glycine
biosynthetic pathway in promoting cancer cell survival and
proliferation. We show that supplemental serine, but not glycine,
is able to rescue the cell death phenotype induced by G9A
inhibition or silencing. In addition, we show that supplemental
serine synergizes with SHMT2 overexpression to enhance notInc.
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G9A Control of Serine Metabolismonly cell survival but also cell proliferation under the condition of
G9A inhibition. Since serine and glycine are interconvertible, the
most obvious explanation for these observations is that the
conversion of serine to glycine generates 5,10-MTHF, a metab-
olite essential for DNA replication and one-carbon metabolism.
This model is also consistent with previous reports that the
mitochondrial SHMT2 has amajor role in the conversion of serine
to glycine and 5,10-MTHF (Herbig et al., 2002; Narkewicz et al.,
1996; Pfendner and Pizer, 1980; Stover et al., 1997; Tibbetts and
Appling, 2010; Yoshida and Kikuchi, 1970). It should be pointed
out that the mitochondrial enzyme glycine cleavage system
catabolizes glycine into carbon dioxide, ammonia, and 5,10-
MTHF (Tibbetts and Appling, 2010). Therefore, supplemental
glycine could be a source of 5,10-MTHF when G9A is inhibited.
However, G9A inhibition markedly reduces the steady-state
levels of both serine and glycine. The demand for serine produc-
tion from supplemental glycine would decrease the 5,10-MTHF
pool. Thus, under the condition of G9A inhibition, 5,10-MTHF
production from the cleavage of supplemental glycine might
not be sufficient to sustain DNA synthesis and one-carbon
metabolism.
Recent studies have identified a genetic mechanism for acti-
vating the serine-glycine biosynthetic pathway in breast cancer
and melanoma through amplification of PHGDH (Locasale
et al., 2011; Possemato et al., 2011). Our findings, coupled to
the observation that G9A is overexpressed in various cancers
(Chen et al., 2010; Cho et al., 2011; Huang et al., 2010; Kondo
et al., 2008), suggest an epigenetic mechanism for activating
this biosynthetic pathway in cancer cells. Thus, by increasing
the amount of glycolic carbon diverted into macromolecule
biosynthesis, G9A contributes to the generation of a meta-
bolic microenvironment favorable for cancer cell survival and
proliferation.
EXPERIMENTAL PROCEDURES
Cell Culture and Reagents
Cells were cultured in DMEM (HyClone SH30022, Thermo Scientific) or MEM
(GIBCO 61100-061, Invitrogen) supplemented with 10% dialyzed FBS (GIBCO
26400-036). BIX01294 (B9311), CQ (C6628), and amino acids were purchased
from Sigma-Aldrich. Stock solutions of 10 mM were made in DMSO (BIX) or
H2O (CQ). In all BIX experiments, DMSO was used as control (untreated).
For rescue experiments, amino acids (100 mM stock in H2O) were added to
MEM at the final concentration of 0.4mM (same as in DMEM). For serine depri-
vation assay, cells were cultured in MEM supplemented with nonessential
amino acids (MEM-NEAA) and then transferred to serine-deficient MEM-
NEAA. Phase contrast images were captured using an Axio Observer
microscope and AxioVision software (Carl Zeiss MicroImaging). Trypan blue
exclusion assay was used to assess cell growth and survival.
Immunoblotting
Cells were suspended in SDS sample buffer and protein concentrations
determined using a protein assay kit (Bio-Rad). Proteins (20 mg) were sepa-
rated on SDS-polyacrylamide gels, transferred to nitrocellulose membranes,
and probed with primary antibodies detailed in Supplemental Experimental
Procedures. Horseradish peroxidase-conjugated goat anti-mouse and anti-
rabbit IgG (Santa Cruz Biotechnology) were used as secondary antibodies.
Proteins were visualized using a SuperSignal West Pico chemiluminescence
kit (Pierce) and quantified with ImageJ (version 1.47d). Films were exposed
for various times for protein quantification within linear range of detection.
For visualization and quantification with the Odyssey system, goat anti-mouse
IRDye 800 or 680 and anti-rabbit IRDye 800 or 680 (LI-COR Biosciences) were
used as secondary antibodies.Cell MImmunofluorescence
Cells were fixed with 4% paraformaldehyde and costained with rabbit anti-
LC3B (3868, Cell Signaling, 1:200) and mouse anti-a-tubulin (B-5-1-2,
Sigma-Aldrich, 1:2000). All secondary fluorescence antibodies (Alexa Fluor
488 and 594) were from Molecular Probes and used at 1:1,000 dilution. Nuclei
were stained with DAPI (D3571, Invitrogen) or Hoechst 33342 (H3570,
Invitrogen). Fluorescent images were captured with an Axio Observer
microscope and AxioVision software. For quantification of LC3B-positive
puncta per cell, approximately 100 cells were counted from a random
selection of four to six 6303 fields independently by two investigators.
Microarray
Total RNA was isolated using Trizol (Invitrogen) from three independent sam-
ples of BE(2)-C cells with or without 5 mM BIX for 24 hr. Affymetrix microarray
was performed using the Human Gene 1.0 ST microarray chip. Data were
normalized, significance determined by ANOVA, and fold change calculated
with the Partek Genomics Suite. GO analysis was performed with DAVID
(Huang et al., 2009) for all differentially expressed genes (R±1.5-fold, p < 0.01).
RNA-Seq
Total RNA was isolated using Trizol from three independent samples of
U2OS cells either untreated or treated with 5 mM BIX for 6 or 24 hr. RNA-seq
libraries were generated with an Illumina TruSeq RNA sample preparation kit
(RS-122-2001) and sequenced using Illumina high-seq 2000 with a read length
of 50 bp with pair ends. RNA-seq reads were mapped to the human genome
(hg19) using TopHat (Trapnell et al., 2009). Only those reads mapped to unique
genomic locations and with <5%mismatches were analyzed further. We used
Cufflinks to measure gene transcripts, and Cuffdiff to identify differentially
expressed genes with a RefSeq GTF file downloaded from Illumina iGenomes
(Roberts et al., 2011). Deferentially expressed genes were fed into DAVID for
functional annotation. Bioconductor (Gentleman et al., 2004) packages were
used to generate heatmap.
qRT-PCR
Total RNA was isolated from three independent samples using Trizol. Reverse
transcription was performed using SuperScript II Reverse Transcriptase
(Invitrogen). Quantitative real-time PCR was performed using a RT2 SYBR
green/Fluorescein PCR master mix (SABiosciences) on an iQ5 real-time
PCR system (Bio-Rad) with primers against ATF4, CCNA2, CCNB1, CCNB2,
CDC25C, PHGDH, PSAT1, PSPH, SHMT1, SHMT2, and B2M (Table S3). All
primer pairs were verified by melting curve analysis following qRT-PCR, with
each primer pair showing a single desired amplification peak. All samples
were normalized to b2 microglobulin mRNA levels.
ChIP-qPCR and ChIP-Seq
ChIP was performed as described (Lee et al., 2006), using 2 3 107 parental,
GFP-overexpressing, or G9A-overexpressing U2OS cells with or without
5 mM BIX for the indicated times. Crosslinked chromatin was sheared through
sonication and immunoprecipitated using ChIP grade mouse anti-H3K9me1
(17–680), rabbit anti-H3K9me2 (17–648), or control mouse IgG or rabbit IgG
(all from Millipore). For qPCR, two independent ChIP samples were analyzed,
and each sample was assayed in triplicate using primers that cover the pro-
moter regions of PHGDH and PSAT1, and the coding region of GAPDH
(detailed in Supplemental Experimental Procedures). For ChIP-seq, libraries
were generated from ChIP samples using an Illumina TruSeq ChIP Sample
Prep kit (IP-202-1012) and sequenced using Illumina high-seq 2000 with a
read length of 50 bp with pair ends. Raw Illumina sequencing reads in the
FASTQ format were cleaned using in-house scripts by trimming sequencing
adaptors and low-quality bases in both ends (Q < 67 in Illumina 1.5). Cleaned
sequences were then mapped to the human genome (hg19) using Novoalign
v2.07. The reads that mapped uniquely to a single genomic locus were used
for peak finding with MACS v1.4 (Zhang et al., 2008), and only those peaks
with false discovery rate (FDR) <1% were compared with RefSeq genes in
the UCSC genome browser.
Metabolite Analysis
GC-MS metabolomic analysis was performed in the University of Utah
Metabolomics Core. Parental, GFP- or G9A-overexpressing U2OS cellsetabolism 18, 896–907, December 3, 2013 ª2013 Elsevier Inc. 905
Cell Metabolism
G9A Control of Serine Metabolismwere cultured in MEM supplemented with 10% dialyzed FBS and were either
untreated or treated with 5 mM BIX for 4 hr. Cells were washed with PBS, har-
vested by trypsin digestion, transferred to a microfuge tube, and frozen on dry
ice. Metabolites were extracted by 80% methanol at 20C and dried by
vacuum centrifugation. Six biological replicate samples (53 106 cells/sample)
were analyzed for each condition. GC-MS analysis was performed with a
Waters GCT Premier mass spectrometer fitted with an Agilent 6890 gas
chromatograph and a Gerstel MPS2 autosampler. Data were collected using
MassLynx 4.1 software (Waters). Metabolites were identified and their peak
area was recorded using QuanLynx. Data were normalized for extraction effi-
ciency and analytical variation by mean centering the area of D4-succinate.
Flux Analysis
U2OS cells with or without overexpression of GFP or G9A were cultured in
either glucose-deficient DMEM (11966-025, Invitogen) or MEM supplemented
with 10% dialyzed FBS and 25 mM [U-13C] glucose (CDLM-3813-1, Cam-
bridge Isotope Laboratories) with or without 5 mM BIX for 16 hr before metab-
olite extraction with 80% methanol. Conversion of [U-13C] glucose to other
metabolites was analyzed by targeted LC-MS/MS using selected reaction
monitoring (SRM) with a 5500 QTRAP mas spectrometer (Yuan et al., 2012).
Three biological replicate samples were analyzed for each condition.
Analysis of Tumor Data Sets
The Versteeg NB88 data set contains 88 primary neuroblastoma tumors of all
stages (Valentijn et al., 2012). Kaplan-Meier analysis was conducted online
(http://r2.amc.nl), and the resulting survival curve and p value (log-rank test)
were downloaded.
Statistics
Data are presented as mean ± SD. Statistics were determined with unpaired,
two-tailed Student’s t test using GraphPad Prism 6.01 for Mac.
ACCESSION NUMBERS
The NCBI Gene Expression Omnibus (GEO) accession number for the micro-
array data reported in this paper is GSE51512.
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